Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Sev ...